Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.53 |
| ▸ | AXL | P30530 | 3/20 | 0.53 |
| ▸ | BRD4 | O60885 | 11/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23766284 | 1.00 | CRBN (0.53) | CRBNAXLBRD4DDB1TNF | |
| SCHEMBL31526946 | 0.94 | CRBN (0.58) | CRBNAXLBRD4DDB1TNF | |
| SCHEMBL17884396 | 0.94 | CRBN (0.58) | CRBNAXLBRD4DDB1TNF | |
| SCHEMBL30786799 | 0.94 | CRBN (0.58) | CRBNAXLBRD4DDB1TNF | |
| SCHEMBL31526908 | 0.94 | CRBN (0.58) | CRBNAXLBRD4DDB1TNF | |
| SCHEMBL17873770 | 0.94 | CRBN (0.58) | CRBNAXLBRD4DDB1TNF | |
| SCHEMBL17873802 | 0.93 | CRBN (0.59) | CRBNAXLBRD4DDB1TNF | |
| SCHEMBL20933080 | 0.92 | CRBN (0.60) | CRBNBRD4DDB1TNFIL1B | |
| SCHEMBL26321035 | 0.91 | CRBN (0.63) | CRBNBRD4DDB1TNFIL1B | |
| SCHEMBL26323874 | 0.91 | CRBN (0.63) | CRBNBRD4DDB1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134104-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2023-02-15 | — | — | EP | disclosed |